mild cognitive impairment
Conditions
Interventions
aMCI treatment group:deep transcranial magnetic stimulation for 4 weeks
aMCI control group:live as usual for 4weeks
Sponsors
The First Affiliated Hospital of China Medical University
Eligibility
Sex/Gender
All
Age
55 Years to 79 Years
Inclusion criteria
Inclusion criteria: aMCI population (50 cases) : 1) Age 55-79 years old; 2) Able to understand instructions and communicate with the experimenter normally; 3) It meets the aMCI scientific research diagnostic criteria proposed by Peterson in 2004, that is, it meets the aMCI diagnostic criteria: a. Subjective memory impairment provided by myself and confirmed by an informed person; b. Objective memory impairment was present. The auditory word learning test was used in this study, and the delayed memory score was lower than 1.5SD under age correction (N5=4 score for 55-59 year olds; 60-69 years old population, N5=3 score; 70-79 years old, N5=2 points); c. Basic cognitive function was retained. This study adopted mini-mental state examination (MMSE) to reach the normal age-adjusted standard (illiterates > 17 points, primary schools > 20 points, secondary schools and above > 24 points); d. Basically intact daily Activities. This study adopted Activities of daily living (ADL) < 23 points; e. does not meet the diagnostic criteria for any type of dementia; 4) No other mental disorders; 5) There were no depressive symptoms, and The Geriatric Depression Scale (GDS-15) was used in this study to evaluate and screen, and the score was < A score of 5 is considered as no depressive symptoms. 6) clinical dementia rating scale (CDR) =0.5 Healthy control (50 cases) : 1) Age 55-79 years old; 2) Able to understand instructions and communicate with the experimenter normally; 3) Normal cognitive function; 4) No depressive symptoms (GDS 30 items<15 points).
Exclusion criteria
Exclusion criteria: 1) There are definite mental and nervous system disorders (such as schizophrenia, alcohol dependence, substance abuse, cerebral hemorrhage, massive cerebral infarction, transient ischemic attack, epilepsy, Parkinson's disease, etc.); 2) History of craniocerebral trauma, coma, general anesthesia in the past 6 months; 3) Can not cooperate with the cognitive test; 4) Patients with dTMS treatment contrainidations (including patients or users of implanted devices such as cardiac pacemakers, implantable defibrillators and neurostimulators, patients with a history of epilepsy, acute cerebral hemorrhage, acute infectious diseases, patients wearing electronic products such as insulin pumps, holters, etc., and patients with body implants; Patients with malignant tumors; Pregnant women and inexpressive children; An open wound; Vascular embolism; Hypoleukocyte, etc.) 5) Use of drugs that affect cognitive function (including cholinesterase inhibitors, memantine hydrochloride, cabalatin, benzodiazepines and antipsychotics, etc.) within 3 months; 7) Other unstable physical diseases that may affect cognitive function include: uncontrolled arrhythmia, hypertension, glycemic disease, acute pulmonary embolism, deep vein thrombosis, recent or unstable fractures, inflammation or traumatic joint injury. 8) Metabolic diseases, obesity, cirrhosis, fatty liver, inflammatory bowel disease, irritable bowel syndrome, asthma, special dietary habits. Take dairy products (yogurt, etc.) or antibiotics within 1 month prior to sampling.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Montreal Cognitive Assessment Scale(MoCA);Auditory vocabulary learning test(AVLT);Trail Making Test(TMT);clock draw test (CDT);Verbal fluency test(VFT);Digit Span Test( DST);function connection(FC);Fractional anisotropy(FA); | — |
Countries
China
Contacts
Public ContactYanqing Tang
The First Affiliated Hospital of China Medical University
Outcome results
None listed